Shenqi Pill Mitigates Renal Interstitial Fibrosis Through Weakening Notch1/Jag1 Pathway.

IF 0.8 4区医学 Q4 UROLOGY & NEPHROLOGY Iranian journal of kidney diseases Pub Date : 2024-05-01 DOI:10.52547/b56av842

Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng

{"title":"Shenqi Pill Mitigates Renal Interstitial Fibrosis Through Weakening Notch1/Jag1 Pathway.","authors":"Hongshu Chen, Yuanxiao Yang, Xiaojie Zhou, Yaorong Feng","doi":"10.52547/b56av842","DOIUrl":null,"url":null,"abstract":"Introduction: Shenqi pill (SQP) can be used to treat various kidney related diseases, but its exact mechanism of action remains unclear. We intended to analyze the role and mechanism of SQP on renal interstitial fibrosis (RIF).Methods: After performing unilateral ureteral obstruction (UUO) surgery following the Institutional Animal Care and Use Committee guidelines, all rats were assigned into the sham group, UUO group, UUO + SQP 1.5 g/kg, UUO + SQP 3 g/kg, and UUO + SQP 6 g/kg groups. After treatment with SQP for 4 weeks, the appearance of kidney, serum creatinine (SCr), and blood urea nitrogen (BUN) levels were monitored in each group. The pathological injury, extracellular matrix (ECM), and Notch1 pathway-related protein levels were measured using H&E staining, Masson staining, immunohistochemistry, and Western blot, respectively.Results: SQP could obviously ameliorate the appearance of the kidney as well as the levels of SCr and BUN in UUO rats (SCr: 67.6 ± 4.64 μM, 59.66 ± 4.96 μM, 48.76 ± 4.44 μM, 40.43 ± 3.02 μM for UUO, low, medium, and high SQP treatment groups; BUN: 9.09 ± 0.97 mM, 7.72 ± 0.61 mM, 5.42 ± 0.42 mM, 4.24 ± 0.34 mM for UUO, low, medium, and high SQP treatment groups; P < .05). SQP also effectively mitigated renal tissue injury in UUO rats (P < .05). Moreover, we uncovered that SQP significantly inhibited Collagen I, α-SMA, Collagen IV, TGF-B1, Notch1, and Jag1 protein expressions in UUO rats kidney (P < .05).Conclusion: Our data elucidated that SQP can alleviate RIF, and the mechanism may be related to the Notch1/Jag1 pathway. DOI: 10.52547/ijkd.7703.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"18 3","pages":"159-167"},"PeriodicalIF":0.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of kidney diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.52547/b56av842","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Shenqi pill (SQP) can be used to treat various kidney related diseases, but its exact mechanism of action remains unclear. We intended to analyze the role and mechanism of SQP on renal interstitial fibrosis (RIF).

Methods: After performing unilateral ureteral obstruction (UUO) surgery following the Institutional Animal Care and Use Committee guidelines, all rats were assigned into the sham group, UUO group, UUO + SQP 1.5 g/kg, UUO + SQP 3 g/kg, and UUO + SQP 6 g/kg groups. After treatment with SQP for 4 weeks, the appearance of kidney, serum creatinine (SCr), and blood urea nitrogen (BUN) levels were monitored in each group. The pathological injury, extracellular matrix (ECM), and Notch1 pathway-related protein levels were measured using H&E staining, Masson staining, immunohistochemistry, and Western blot, respectively.

Results: SQP could obviously ameliorate the appearance of the kidney as well as the levels of SCr and BUN in UUO rats (SCr: 67.6 ± 4.64 μM, 59.66 ± 4.96 μM, 48.76 ± 4.44 μM, 40.43 ± 3.02 μM for UUO, low, medium, and high SQP treatment groups; BUN: 9.09 ± 0.97 mM, 7.72 ± 0.61 mM, 5.42 ± 0.42 mM, 4.24 ± 0.34 mM for UUO, low, medium, and high SQP treatment groups; P < .05). SQP also effectively mitigated renal tissue injury in UUO rats (P < .05). Moreover, we uncovered that SQP significantly inhibited Collagen I, α-SMA, Collagen IV, TGF-B1, Notch1, and Jag1 protein expressions in UUO rats kidney (P < .05).

Conclusion: Our data elucidated that SQP can alleviate RIF, and the mechanism may be related to the Notch1/Jag1 pathway. DOI: 10.52547/ijkd.7703.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

神气丸通过削弱Notch1/Jag1通路缓解肾间质纤维化

简介神气丸（SQP）可用于治疗多种肾脏相关疾病，但其确切的作用机制尚不清楚。我们旨在分析神气丸对肾间质纤维化（RIF）的作用和机制：方法：按照动物护理和使用委员会的指导原则进行单侧输尿管梗阻（UUO）手术后，将所有大鼠分为假组、UUO 组、UUO + SQP 1.5 g/kg 组、UUO + SQP 3 g/kg 组和 UUO + SQP 6 g/kg 组。使用 SQP 治疗 4 周后，监测各组的肾脏外观、血清肌酐（SCr）和血尿素氮（BUN）水平。采用H&E染色、Masson染色、免疫组化和Western blot等方法分别检测病理损伤、细胞外基质（ECM）和Notch1通路相关蛋白水平：结果：SQP 能明显改善 UUO 大鼠肾脏的外观以及 SCr 和 BUN 的水平（SCr：UUO、低、中、高 SQP 治疗组的 SCr：67.6 ± 4.64 μM、59.66 ± 4.96 μM、48.76 ± 4.44 μM、40.43 ± 3.02 μM；UUO、低、中、高 SQP 治疗组的 BUN：9.09 ± 0.97 mM、7.72 ± 0.61 mM、5.42 ± 0.42 mM、4.24 ± 0.34 mM；P < .05）。SQP 还能有效减轻 UUO 大鼠的肾组织损伤（P < .05）。此外，我们还发现 SQP 能显著抑制 UUO 大鼠肾脏中胶原 I、α-SMA、胶原 IV、TGF-B1、Notch1 和 Jag1 蛋白的表达（P < .05）：我们的数据阐明了SQP能缓解RIF，其机制可能与Notch1/Jag1通路有关。DOI: 10.52547/ijkd.7703.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Iranian journal of kidney diseases UROLOGY & NEPHROLOGY-

CiteScore

2.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Iranian Journal of Kidney Diseases (IJKD), a peer-reviewed journal in English, is the official publication of the Iranian Society of Nephrology. The aim of the IJKD is the worldwide reflection of the knowledge produced by the scientists and clinicians in nephrology. Published quarterly, the IJKD provides a new platform for advancement of the field. The journal’s objective is to serve as a focal point for debates and exchange of knowledge and experience among researchers in a global context. Original papers, case reports, and invited reviews on all aspects of the kidney diseases, hypertension, dialysis, and transplantation will be covered by the IJKD. Research on the basic science, clinical practice, and socio-economics of renal health are all welcomed by the editors of the journal.